Market OverviewTibsovo (ivosidenib) is a targeted cancer therapy developed by Agios Pharmaceuticals, Inc. It is an oral, small molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is mutated in various types of cancers, including acute myeloid leukemia (AML), cholangiocarcinoma, and glioma. Tibs...